Published on March 2, 2014
Presentation By: Abhishek Gupta Jyoti Sawana
Started by ‘Ran’bir Singh & Gur‘bax’ Singh in 1937. They sold the company to their cousin “Mohan Singh” in 1952. Company went public in 1973. Entered the US markets in 1998, other major countries- Brazil, Russia, China and Europe.
Indian Multinational Pharmaceutical company incorporated in 1961. “Daiichi Sankyo” acquired a controlling interest (50.1%) in 2008. Exports to 125 countries, with manufacturing facilities available in 8 of them.
Former CEO, Malvinder Singh and his brother sold their share of Ranbaxy for $2 Billion in 2008 to Daiichi- Sankyo. Current CEO of Ranbaxy: Mr. Arun Sawhney. Ranbaxy generated a revenue of $2 Billion in 2012, EBITDA- $290 Million in 2012. Listed in the NSE(RANBAXY) and the BSE(500359).
Currently Ranbaxy has 11 plants in India: Mohali, Punjab Toansa, Punjab Dewas, MP Paonta Sahib, HP Okhla, New Delhi Jejuri, Maharashtra Ponda, Goa Paonta Sahib, HP(2nd Plant) Ghirongi, MP Mohali, Punjab(2nd Plant) Baddi, HP Apart from these, Ranbaxy has a number of externally hired laboratories in India as well.
WHISTLE BLOWERS:- In 200405, Dinesh Thakur and Rajinder Kumar blew the whistle on Ranbaxy’s fabrication of drug test reports. As a result, in 2008, Ranbaxy Laboratories ltd. was issued 2 warning letters by the FDA and an import alert on 2 Indian manufacturing plants (Dewas & Poanta Sahib). Later the same year, the USFDA banned all products from the Toansa, Poanta Sahib plants.
February 2012, three batches of the proton-pump inhibitor Pantoprazole were recalled in the Netherlands due to the presence of impurities. November 2012, Ranbaxy halted production and recalled forty-one lots of Atorvastatin due to glass particles being found in some bottles.
In May 2013, the company pleaded guilty to felony charges related to drug safety and agreed to pay $500 million in civil and criminal fines under the settlement agreement with the US department of justice. As per the Whistleblower agreement, Dinesh Thakur received $48.1 million for his efforts in bringing Ranbaxy to justice.
September 2013, further problems were reported, including apparent human hair in a tablet, oil spots on other tablets, toilet facilities without running water, and a failure to instruct employees to wash their hands after using the toilet. Due to the above, Ranbaxy is prohibited from manufacturing FDAregulated drugs at the Mohali facility until the company complies with U.S. drug manufacturing requirements.
In January 2014, the US-FDA, in one of its inspection found irregularities from the data from the Toansa plant. The US-FDA banned all the products from this plant as well. “Our inspection of the quality control analytical and microbiology laboratories found the facility to be in significant disrepair,” - US FDA inspector.
Ranbaxy’s Toansa factory, with its inception in 1986, is one of the oldest active pharmaceutical ingredient (API) manufacturing facilities in the country. Till the latest US ban was imposed on the unit, it was catering to over 70 per cent of Ranbaxy’s captive requirement for API or raw material used in medicine formulations. US FDA Form 483 highlighted eight serious deviations in Ranbaxy’s Toansa factory. These included presence of flies through broken windows, building up of melting ice in refrigerator where drug samples were stored, nonmaintenance of analytical instruments, etc.
"While we continue to assess the overall business impact on all aspects in our value chain, our direct sales impact because of the Toansa facility issue will be limited." - Arun Sawhney (CEO, Ranbaxy) "What we know publicly is that the company has spent a lot of money upgrading its facilities, which is a part of the solution, The bigger issue is changing the culture of the company, which will take inspired leadership, not just external consultants.” – Dinesh Thakur(Former Employee, Whistleblower)
“This is a complete cover-up act by the management. The management must look for the right kind of solutions to address the problem, instead of shifting the blame on employees.” a company employee told Business Standard, on conditions of anonymity. “We are supporting and focusing on this action as a matter of high priority, For further approach to solve a series of problems, we think we need a comprehensive policy after this. We want to go back and prepare a more aggressive, more drastic response.” Daiichi Sankyo Senior Executive Officer Manabu Sakai
CBS News Fox News CNN The Economic Times Business-Standard Fortune Magazine- Investigative article “Dirty Medicine” Wikipedia Reuters Money Control.com BSE Ranbaxy website DD News- “The Big Picture”
Ranbaxy crisis - Get latest news on Ranbaxy crisis. Read Breaking News on Ranbaxy crisis updated and published at Zee News
Annual Reports & Presentations. Tell a Friend Print ... Ranbaxy Archives; Annual Reports; Investors Relations; Media Kit; Press Releases; Sitemap; Employee ...
Hier sollte eine Beschreibung angezeigt werden, diese Seite lässt dies jedoch nicht zu.
Evidence of a lack of crisis management concern? Ranbaxy Pharmaceuticals Inc. is recalling more than 40 lots of atorvastatin pills — the generic version ...
Amidst crisis, Tata Group's pharma ... Barbhaiya, a US citizen of India origin, moved to India in 2002 to take up a role with Ranbaxy and then floated ...
The Johnson & Johnson Tylenol crisis is an example of how an organization should communicate with the various publics during a crisis. The ...
The Ranbaxy crisis cannot be viewed in isolation. Historically, even the big innovator pharma companies like Pfizer Inc, GlaxoSmithKline Pharmaceuticals